

Market Outlook

The Nifty 50 closed today at **26,205**, up **320 points** or **1.23%**, after moving in a range of **25,843–26,215**, reflecting strong intraday momentum. Buying interest was broad-based, with **banking, realty and metals** leading the rally, while select IT stocks saw mild profit-taking. The index reclaimed key short-term averages, reinforcing the positive undertone. **Immediate support now lies at 26,000–25,900**, while **resistance is placed at 26,250–26,350**. Overall sentiment remains bullish with stock-specific action dominating.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	26205	1.23
SENSEX	85609	1.20
BANKNIFTY	59528	1.20
INDIA VIX	11.96	-2.25

FII Statistics


FII F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	790.45	2.02%
Index Options	-6858.54	30.31%
Stock Futures	1778.70	-0.06%
Stock Options	-632.16	65.94%

FII & DII Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	4778.03	-12449	-122669
DII	6247.93	68993	511443

FII Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
BHARTIARTL	36720213	29.12	507.86
HDFCBANK	10553283	-3.27	-21.99
RELIANCE	8561296	8.62	-6.51
SBIN	8480096	8.49	52.55
ITC	7833650	5.12	39.56
ETERNAL	7824771	-11.29	-24.95
BAJFINANCE	6621753	-3.36	53.24
ICICIBANK	6155439	8.02	-21.05
POWERGRID	5550881	-7.54	-31.05
ONGC	5111527	-1.82	-19.49


NIFTY

Nifty	26381.20
OI (In contracts)	199029
CHANGE IN OI (%)	2.60
PRICE CHANGE (%)	1.30
IMPLICATION	LONG BUILDUP

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
SAMMAANCAP	158	3.50	24579	23.60
SAIL	137.96	3.90	33056	12.20
UNOMINDA	1330	2.90	8456	11.80
KAYNES	5838	0.30	17898	10.60
BHEL	291.3	2.30	21449	9.80


BANKNIFTY

Banknifty	59817.20
OI (In contracts)	44870
CHANGE IN OI (%)	9.60
PRICE CHANGE (%)	1.10
IMPLICATION	LONG BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
ADANIET	2326.4	-0.90	49965	7.70
LICI	901.45	0.00	13047	4.90
TIINDIA	2901.7	0.00	10414	3.50
BHARTIARTL	2139.9	-1.40	93303	3.10
EICHERMOT	7226.5	-0.20	17480	0.60

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
HEROMOTOCO	3075900	2665650	1.15
AUBANK	7234000	6503000	1.11
PETRONET	18809600	16951200	1.11
VOLTAS	3904500	3511875	1.11
CANBK	127811250	119022750	1.07
SBILIFE	2985000	2784000	1.07
SBIN	44296500	41892750	1.06
FEDERALBNK	47785000	45900000	1.04
EICHERMOT	2666550	2638275	1.01
ABCAPITAL	19554800	20376300	0.96

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
PATANJALI	3325500	9145800	0.36
PPLPHARMA	6678875	17561000	0.38
TATASTEEL	114658500	298611500	0.38
TMPV	34356800	87964800	0.39
KAYNES	1071400	2667900	0.4
NCC	10872900	26605800	0.41
SUZLON	89798500	215184125	0.42
YESBANK	243637400	580948000	0.42
DELHIVERY	10150900	23713100	0.43
NESTLEIND	2363500	5499000	0.43

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2359	2391	2340	2307	2288
ADANIPTS	1536	1554	1515	1497	1476
APOLLOHOSP	7480	7522	7413	7371	7303
ASIANPAINT	2907	2926	2893	2875	2860
AXISBANK	1305	1314	1291	1282	1267
BAJAJ-AUTO	9282	9342	9181	9121	9020
BAJAJFINSV	2128	2156	2075	2047	1995
BAJFINANCE	1029	1040	1009	998	978
BEL	420	423	416	413	408
BHARTIARTL	2155	2170	2133	2117	2095
CIPLA	1540	1546	1528	1522	1510
COALINDIA	381	384	377	375	371
DRREDDY	1264	1271	1253	1246	1235
EICHERMOT	7279	7332	7247	7194	7162
ETERNAL	311	313	307	305	301
GRASIM	2777	2796	2743	2725	2691
HCLTECH	1641	1653	1627	1615	1602
HDFCBANK	1018	1028	1002	993	976
HDFCLIFE	799	807	782	773	757
HINDALCO	811	817	801	795	786
HINDUNILVR	2440	2447	2427	2420	2407
ICICIBANK	1387	1393	1378	1372	1363
INDIGO	5963	6006	5886	5843	5766
INFY	1571	1580	1556	1547	1532
ITC	407	408	405	404	403

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	313	316	308	305	300
JSWSTEEL	1175	1190	1147	1132	1105
KOTAKBANK	2129	2143	2105	2090	2066
LT	4122	4159	4067	4030	3975
M&M	3732	3751	3712	3693	3673
MARUTI	16356	16460	16213	16109	15966
MAXHEALTH	1178	1186	1170	1162	1154
NESTLEIND	1294	1303	1282	1273	1260
NTPC	331	334	326	323	319
ONGC	251	252	249	247	245
POWERGRID	280	284	275	272	267
RELIANCE	1587	1597	1568	1558	1539
SBILIFE	2053	2064	2044	2034	2025
SBIN	1000	1010	995	985	980
SHRIRAMFIN	868	875	856	849	837
SUNPHARMA	1824	1836	1803	1792	1771
TATACONSUM	1203	1214	1184	1174	1154
TATASTEEL	172	173	170	169	167
TCS	3207	3229	3173	3151	3118
TECHM	1539	1548	1522	1512	1495
TITAN	3943	3969	3908	3882	3847
TMPV	366	370	361	357	352
TRENT	4382	4441	4326	4267	4211
ULTRACEMCO	11909	11979	11779	11709	11579
WIPRO	254	256	250	248	244

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results